What's in Halozyme Therapeutics's pipeline?

Halozyme Therapeutics has 6 drugs in our index: 5 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Halozyme Therapeutics's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/halozyme-therapeutics.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Halozyme Therapeutics — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Halozyme Therapeutics pipeline: 5 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Target	Area
large protein molecule	large protein molecule	marketed
recombinant human hyaluronidase	recombinant human hyaluronidase	marketed
regular human insulin	regular human insulin	marketed
recombinant human hyaluronidase PH20	recombinant human hyaluronidase PH20	marketed
Humalog	Humalog	marketed	Insulin receptor	Metabolic

Therapeutic area mix

Metabolic · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Halozyme Therapeutics:

Cite this brief

Drug Landscape (2026). Halozyme Therapeutics — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/halozyme-therapeutics. Accessed 2026-05-16.